timothy sykes logo
SXTP Stock Grinds Higher As Traders Track Volatile Price Action Thumbnail

SXTP Stock Grinds Higher As Traders Track Volatile Price Action

JACK KELLOGG•UPDATED OCT. 6, 2026, 8:32 AM ET
Reviewed by Ellis Hobbsand Fact-checked by Matt Monaco

60 Degrees Pharmaceuticals Inc. faces intensified pressure after negative trial data, as stocks have been trading down by -20.83 percent.

Key Takeaways

  • SXTP has climbed from roughly $0.85 to the mid-$1.40s over recent sessions, showing a short-term uptrend with sharp intraday swings.
  • 60 Degrees Pharmaceuticals Inc. posts about $1.0M in annual revenue but runs steep losses, with deeply negative profit margins and heavy cash burn.
  • SXTP holds just over $1.0M in cash and maintains a current ratio above 2.0, signaling near-term liquidity but limited long-term cushion.
  • Intraday SXTP trading shows repeated spikes above $1.50 followed by quick fades, a pattern momentum traders watch for scalps and potential breakouts.

Candlestick Chart

Live Update At 08:32:02 EDT: On Tuesday, October 06, 2026 60 Degrees Pharmaceuticals Inc. stock [NASDAQ: SXTP] is trending down by -20.83%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

SXTP, the ticker for 60 Degrees Pharmaceuticals Inc., is a classic high-risk, low-float biotech-style name that many small-cap traders gravitate toward. On the surface, the numbers look rough. The company generated about $1.0M in revenue over the latest period, but profit margins are extremely negative. SXTP’s EBIT margin sits around -674%, and net profit margins are even worse. In simple terms, for every dollar 60 Degrees Pharmaceuticals Inc. brings in, it spends several dollars more.

The income statement shows quarterly revenue of roughly $207,900 against total expenses near $2.48M, producing a net loss of about $2.26M, or roughly -$0.90 per share. That kind of burn rate matters. Cash on the balance sheet is about $1.02M, down from $3.34M at the start of the period, and free cash flow is about -$2.32M.

Still, SXTP carries working capital of more than $2.1M and a current ratio around 2.3, which tells traders the company can handle near-term bills. Long-term, though, 60 Degrees Pharmaceuticals Inc. will likely need more capital, a key overhang that often shapes how SXTP trades.

Why Traders Are Watching SXTP’s Momentum

On the chart, SXTP has quietly staged a strong percentage move that momentum traders love to dissect. Over the past couple of weeks, SXTP climbed from sub-$1.00 levels — closing near $0.85–$0.95 on weaker days — to recent closes in the $1.25–$1.44 range. That’s a sizable percentage run, even if the absolute price looks low. For active trading, percentage swings matter far more than nominal price.

Daily candles for SXTP show a pattern of higher lows: from around $0.85 and $0.90, to $0.92–$0.96, then into the $1.01–$1.17 zone, and now into the mid-$1.20s and above. That stair-step pattern suggests 60 Degrees Pharmaceuticals Inc. is building a short-term uptrend. At the same time, intraday volatility is intense. Pre-market and early-session SXTP prints show rapid moves from around $1.30 to $1.79 and back toward the mid-$1.40s in very short windows.

For day traders, that’s the playground. SXTP repeatedly spikes over $1.50, with wicks as high as the $1.70s, then fades back toward support zones around $1.35–$1.45. That kind of action often comes from a mix of low float, tight supply, and reactive trading algorithms. The key for 60 Degrees Pharmaceuticals Inc. watchers is whether these spikes start holding above $1.60–$1.70 or keep getting stuffed.

If SXTP can base above prior resistance near $1.30–$1.35, traders will treat that level as a line in the sand. Lose that range with volume, and the recent uptrend in 60 Degrees Pharmaceuticals Inc. starts to look like a failed bounce rather than a sustainable push.

Conclusion

Putting it all together, SXTP is the type of ticker that fits the “hot but fragile” profile. The chart shows a clear bounce from under $1.00 into the mid-$1.40s, with daily ranges that give skilled traders plenty of room to work. At the same time, the fundamentals of 60 Degrees Pharmaceuticals Inc. are deeply red. Heavy operating losses, negative returns on assets, and fast cash burn tell a simple story: SXTP trades more on momentum and sentiment than on current earnings power.

That doesn’t make SXTP untradeable; it defines the playbook. Short-term traders focus on price levels, volume surges, and intraday support and resistance. Long-term fundamentals serve as a backdrop, reminding traders that 60 Degrees Pharmaceuticals Inc. may need future dilutions or financings to survive. Every SXTP spike has to be judged against that risk.

For active market participants studying SXTP, this is exactly the environment where discipline matters. As Tim Sykes likes to say, “The market doesn’t care about your opinions, only your discipline and your preparation.” As millionaire penny stock trader and teacher Tim Sykes, says, “It’s better to go home at zero than to go home in the red.”. For 60 Degrees Pharmaceuticals Inc., that means treating every SXTP move as a trading setup — not a promise — and managing risk as if the next candle can do anything. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:


How much has this post helped you?



Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”